Targeting Homologous Recombination Repair in Cancer - DNA Repair in Cancer Therapy - page 155

330. Krogan NJ, LamMH, Fillingham J, et al. Proteasome involvement
in the repair of DNA double-strand breaks. Mol Cell 2004;16(6):
1027 e 34.
331. Blickwedehl J, McEvoy S, Wong I, et al. Proteasomes and pro-
teasome activator 200 kDa (PA200) accumulate on chromatin in
response to ionizing radiation. Radiat Res 2007;167(6):663 e 74.
332. Jacquemont C, Taniguchi T. Proteasome function is required for
DNA damage response and fanconi anemia pathway activation.
Cancer Res 2007;67(15):7395 e 405.
333. Murakawa Y, Sonoda E, Barber LJ, et al. Inhibitors of the pro-
teasome suppress homologous DNA recombination in mamma-
lian cells. Cancer Res 2007;67(18):8536 e 43.
334. Shi W, Ma Z, Willers H, et al. Disassembly of MDC1 foci is
controlled by ubiquitin-proteasome-dependent degradation.
J Biol Chem 2008;283(46):31608 e 16.
335. Roccaro AM, Vacca A, Ribatti D. Bortezomib in the treatment of
cancer. Recent Pat Anticancer Drug Discov 2006;1(3):397 e 403.
336. Chirnomas D, Taniguchi T, de la Vega M, et al. Chemo-
sensitization to cisplatin by inhibitors of the Fanconi anemia/
BRCA pathway. Mol Cancer Ther 2006;5(4):952 e 61.
337. Dupre A, Boyer-Chatenet L, Sattler RM, et al. A forward chemical
genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1
complex. Nat Chem Biol 2008;4(2):119 e 25.
338. Rass E, Grabarz A, Plo I, Gautier J, Bertrand P, Lopez BS. Role of
Mre11 in chromosomal nonhomologous end joining in mamma-
lian cells. Nat Struct Mol Biol 2009;16(8):819 e 24.
339. Harari PM, Allen GW, Bonner JA. Biology of interactions: anti-
epidermal growth factor receptor agents. J Clin Oncol 2007;25(26):
4057 e 65.
340. Chinnaiyan P, Huang S, Vallabhaneni G, et al. Mechanisms of
enhanced radiation response following epidermal growth factor
receptor signaling inhibition by erlotinib (Tarceva). Cancer Res
2005;65(8):3328 e 35.
341. Ko JC, Ciou SC, Jhan JY, et al. Roles of MKK1/2-ERK1/2 and
phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-
induced Rad51 suppression and cytotoxicity in human non-small
cell lung cancer cells. Mol Cancer Res 2009;7(8):1378 e 89.
342. Nyati MK, Morgan MA, Feng FY, Lawrence TS. Integration of
EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006;
6(11):876 e 85.
343. Ganapathipillai SS, Medova M, Aebersold DM, et al. Coupling of
mutated Met variants to DNA repair via Abl and Rad51. Cancer
Res 2008;68(14):5769 e 77.
344. Welsh JW, Mahadevan D, Ellsworth R, Cooke L, Bearss D, Stea B.
The c-Met receptor tyrosine kinase inhibitor MP470 radio-
sensitizes glioblastoma cells. Radiat Oncol 2009;4:69.
345. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer
therapy. J Clin Oncol 2009;27(32):5459 e 68.
346. Kotian S, Liyanarachchi S, Zelent A, Parvin JD. Histone deace-
tylases 9 and 10 are required for homologous recombination.
J Biol Chem 2011. January 18; doi: 10.1074/jbc.C110.194233.
347. Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM,
Buggy JJ. HDAC inhibitor PCI-24781 decreases RAD51 expres-
sion and inhibits homologous recombination. Proc Natl Acad Sci
USA 2007;104(49):19482 e 7.
348. Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-
Chk1 pathways in DNA damage signaling and cancer. Adv Cancer
Res 2010;108:73 e 112.
349. Morgan MA, Parsels LA, Zhao L, et al. Mechanism of radio-
sensitization by the Chk1/2 inhibitor AZD7762 involves abro-
gation of the G2 checkpoint and inhibition of homologous
recombinational DNA repair. Cancer Res 2010;70(12):4972 e 81.
350. Koniaras K, Cuddihy AR, Christopoulos H, Hogg A,
O'Connell MJ. Inhibition of Chk1-dependent G2 DNA damage

checkpoint radiosensitizes p53 mutant human cells. Oncogene
2001;20(51):7453 e 63.
351. Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de
Vries A, Jonkers J. High incidence of protein-truncating TP53
mutations in BRCA1-related breast cancer. Cancer Res 2009;69(8):
3625 e 33.
352. Chen CC, Kennedy RD, Sidi S, Look AT, D'Andrea A. Chk1
inhibition as a strategy for targeting Fanconi Anemia (FA) DNA
repair pathway deficient tumors. Mol Cancer 2009;8:24.
353. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a para-
digm for cell signalling and cancer. Nat Rev Mol Cell Biol 2008;
9(10):759 e 69.
354. Bryant HE, Helleday T. Inhibition of poly (ADP-ribose) poly-
merase activates ATM which is required for subsequent homol-
ogous recombination repair. Nucleic Acids Res 2006;34(6):1685 e 91.
355. Weston VJ, Oldreive CE, Skowronska A, et al. The PARP inhibitor
olaparib induces significant killing of ATM-deficient lymphoid
tumor cells in vitro and in vivo. Blood 116(22): 4578-87.
356. Kennedy RD, Chen CC, Stuckert P, et al. Fanconi anemia
pathway-deficient tumor cells are hypersensitive to inhibition of
ataxia telangiectasia mutated. J Clin Invest 2007;117(5):1440 e 9.
357. Anderson VE, Walton MI, Eve PD, et al. CCT241533 Is a potent
and selective inhibitor of Chk2 that potentiates the cytotoxicity of
PARP inhibitors. Cancer Res 2011;71(2):463 e 72.
358. Bentzen SM, Trotti A. Evaluation of early and late toxicities in
chemoradiation trials. J Clin Oncol 2007;25(26):4096 e 103.
359. Chien KR. Herceptin and the heart e a molecular modifier of
cardiac failure. N Engl J Med 2006;354(8):789 e 90.
360. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer
therapeutic agent imatinib mesylate. Nat Med 2006;12(8):908 e 16.
361. Nanda A, Dias-Santagata DC, Stubbs H, et al. Unusual tumor
response and toxicity from radiation and concurrent erlotinib for
non-small-cell lung cancer. Clin Lung Cancer 2008;9(5):285 e 7.
362. Tsuboi M, Le Chevalier T. Interstitial lung disease in patients with
non-small-cell lung cancer treated with epidermal growth factor
receptor inhibitors. Med Oncol 2006;23(2):161 e 70.
363. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose)
polymerase in tumors from BRCA mutation carriers. N Engl J
Med 2009;361(2):123 e 34.
364. Chemotherapy in non-small cell lung cancer. a meta-analysis
using updated data on individual patients from 52 randomised
clinical trials. Non-small Cell Lung Cancer Collaborative Group.
BMJ 1995;311(7010):899 e 909.
365. Boles NC, Peddibhotla S, Chen AJ, Goodell MA, Rosen JM. Chk1
haploinsufficiency results in anemia and defective erythropoiesis.
PLoS One 2010;5(1). e8581.
366. Alberts B. DNA replication and recombination. Nature 2003;
421(6921):431 e 5.
367. Huen MS, Chen J. Assembly of checkpoint and repair machin-
eries at DNA damage sites. Trends Biochem Sci 2010;35(2):101 e 8.
368. Warmerdam DO, Kanaar R. Dealing with DNA damage: rela-
tionships between checkpoint and repair pathways. Mutat Res
704(1-3): 2-11.
369. Golding SE, Morgan RN, Adams BR, Hawkins AJ, Povirk LF,
Valerie K. Pro-survival AKT and ERK signaling from EGFR and
mutant EGFRvIII enhances DNA double-strand break repair in
human glioma cells. Cancer Biol Ther 2009;8(8).
370. Yap TA, Sandhu SK, Carden CP, de Bono JS. Poly(ADP-ribose)
polymerase (PARP) inhibitors: Exploiting a synthetic lethal
strategy in the clinic. CA Cancer J Clin 61(1): 31-49.
371. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in
non-small-cell lung cancer and cisplatin-based adjuvant chemo-
therapy. N Engl J Med 2006;355(10):983 e 91.
372. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on
quantitative excision repair cross-complementing 1 mRNA